Keyphrases
Recombinant FIX
83%
Cyclic GMP
83%
Factor 9
83%
Hemophilia B
83%
Optimal Therapy
35%
Milk
35%
Coagulation Proteins
23%
Transgenic pig
23%
Hemophilia Patients
23%
Human Factor IX (hFIX)
23%
Bioprocess Engineering
14%
Episode Frequency
14%
Lyophilized Protein
14%
Hemostatic Property
14%
Bleeding Disorders
11%
Protein Factor
11%
Success Probability
11%
Development Experience
11%
Recombinant Human
11%
Oral Dosage Forms
11%
Pharmacokinetic Properties
11%
Safe Therapy
11%
Cognitive Impairment
11%
Clinical Trials
11%
Plasma-derived
11%
Transgenic Animals
11%
Effective Therapy
11%
Nebraska
11%
Bleeding Episodes
11%
Chronic Pain
11%
Colorado State University
11%
Development State
11%
Mouse Model
11%
Patient Demographics
11%
Clinical Grade
11%
High Probability
11%
Biopharmaceutical Development
11%
Congenital Deficiency
11%
Bioengineering Technology
11%
Recombinant Protein Production
11%
Chapel Hill
11%
Genetic Engineering
11%
Small Fraction
11%
Limited Supply
11%
Scale-up Production
11%
Pharmacology, Toxicology and Pharmaceutical Science
Haemophilia B
100%
Blood Clotting Factor 9
83%
Haemophilia
18%
Transgenic Pig
18%
Blood Clotting Factor 9 Concentrate
11%
Recombinant Protein
9%
Chronic Pain
9%
Cognitive Defect
9%
Transgenic Animal
9%
Clinical Trial
9%
Pharmacokinetics
9%
Dosage Forms
9%
Good Manufacturing Practice
9%
Mouse
9%
Bleeding Disorder
9%
Mouse Model
9%
Hemostatic Agent
9%
Medicine and Dentistry
Factor IX
83%
Haemophilia B
83%
Haemophilia
18%
Blood Clotting Factor 9 Concentrate
11%
Pharmacokinetics
9%
Patient Population
9%
Chronic Pain
9%
Recombinant Protein
9%
Bleeding Disorder
9%
Transgenic Animal
9%
Biopharmaceuticals
9%
Clinical Trial
9%
Health Care Cost
9%
Cognitive Defect
9%
Hemostat
9%